Articles On Living Cell Technologies (ASX:LCT)

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Living Cell Technologies (LCT) is partnering with La Trobe University to conduct multiple pre-clinical studies using AI116 to treat dementia LCT will employ state-of-the-art experimental techniques to aid the process, which will offer in...

Living Cell Technologies (ASX: LCT) has entered into a research agreement with Melbourne’s La Trobe University for a range of pre-clinical studies assessing the effect of cannabinoid-based combination drug AI-116 on patients with dementia....

Futures are predicting that the ASX will open in the red to end the week, bucking the trend on a week full of positive openings. Meanwhile, Wall Street eagerly awaits US job data. Bitcoin also as experienced a decline overnight, down by...

ASX to open lower today after a late selloff on Wall Street The US Fed’s preferred inflation posted another increase Aussie home prices are staging a recovery – Corelogic report   Australian shares are set to open lower on Friday after a...

Melbourne-headquartered biotechnology company Living Cell Technologies (ASX: LCT) made significant strides in its efforts to create a pharmaceutical company with a diversified product candidate pipeline during a busy June quarter. Boosted b...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Living Cell Technologies (ASX: LCT) has filed a provisional patent application over combination drug candidate AI-116 which contains cannabidiol (CBD) and an off-paten...

This content is created by Smallcaps Authors. [Author : Colin Hay] Biotechnology company Living Cell Technologies (ASX: LCT) is preparing to take the next step in a major makeover with a proposal to be put to shareholders to change its na...

AVITA receives US FDA premarket approval for its RECELL System Living Cell falls after saying it will enact a temporary pause on pig herd facility Oneview Healthcare signs material deal with NYSE-listed Baxter   Regenerative medicine comp...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Living Cell Technologies (ASX: LCT) has released a market update on its planned NTCELL clinical trial program for Parkinson’s disease. The company has confirmed that c...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Biotechnology company Living Cell Technologies (ASX: LCT) has appointed experienced Australian research scientist Dr James A Mckenna to the role of chief scientific of...

Living Cell Technologies (LCT) launches a $2.5 million capital raise with Alignment Capital to develop its NTCELL project LCT plans to raise the funds through a $1.2 million share placement, a $750,000 entitlement offer, and an over-allo...

The ASX fell today because US data gave Wall Street the willies on Friday A month’s worth of shipping data shows coal shipments to China are on the rise Qantas celebrates last week’s $1bn profit by slashing regional services. Again   Toda...

Wall Street slump leads the ASX into an early morning drop. Thanks, Obama Benchmark strides deeper into the red, graceful as a moose on rollerskates New Age Exploration has a mystical moment at the peak of Mount Profit Well, it’s safe to...

Living Cell Technologies (LCT) completes stage one of its use of artificial intelligence in the planned manufacturing of NTCELL in Sydney, AustraliaUnder an agreement with OptiCellAI, the two companies will ensure the high quality encapsula...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

Living Cell Technologies (ASX:LCT) has advanced its Parkinson’s disease research with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL.

Highlights The healthcare sector comprises stocks from diversified backgrounds, including healthcare services, healthcare equipment, pharmaceuticals, biotechnology, etc. Last month, Living Cell Technologies (ASX:LCT) raised AU$1.285 mi...

Biotech company Living Cell Technologies (LCT) raises $1.285 million through a private placement to boost its research into Parkinson’s Disease The company issued 257 million new fully-paid ordinary shares to professional and sophisticated...

Living Cell Technologies (LCT) enters a trading halt as the company awaits more details in regards to an upcoming capital raise Trading of shares will be paused until Tuesday, May 31 or until LCT releases more information Earlier this week...

Living Cell Technologies (ASX:LCT) says artificial intelligence will be applied to its research into Parkinson’s disease under a new agreement with OptiCellAI.

Highlights LCT has marked a major leap in its groundbreaking research to combat Parkinson’s disease, which affects millions of people worldwide. The company is set to apply AI in NTCELL research to augment the quality of its third clin...

Oneview extends supply deal to BJC’s hospital beds LCT will start to use artificial intelligence in its research AFT Pharma’s solid FY22 Oneview extends hospital deal with BCJ Health Healthcare software company Oneview Healthcare (ASX:ONE...

ASX to open the lower on the first day of the new Labor government Experts say there will be renewed focus on renewables under the new PM Germany’s producer prices soar by a record 33% Local shares are set to drop lower on the first day o...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Living Cell Technologies (ASX:LCT) says it has advanced plans for a third clinical trial of NTCELL in Parkinson’s disease.

Highlights The Australian healthcare sector includes companies engaged in biotechnology and research, food and drug retailing, health care equipment, service providers, and pharmaceuticals. On a YTD basis, the healthcare index is runni...

The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial...

Living Cell Technologies (LCT) receives valid applications for new shares and new options under its rights issue which closed on December 21 seeing big shortfall The company initially announced on November 15 it was aiming to raise up to $...

There were few major catalysts on Thursday, as the ASX traded flat in a relatively cruisy session following some solid gains this week. Broadly speaking, the ASX has tracked global stock markets higher after a rocky selloff last week that f...

Today is the deadline for ASX companies to submit their quarterlies. Stockhead has recapped the Top 5 winners in morning trade, as investors responded to the latest earnings report cards. 9Spokes (ASX:9SP) This New Zealand business is a bus...

Just like yesterday the ASX rallied for most of the day but retreated in the afternoon and today closed in the red. The ASX 200 was down 0.08% at 7,375 points. Another difference from yesterday was tech was the best sector gaining 1.7% whil...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Living Cell Technologies (LCT) secures funding for its third clinical trial of NTCELL in Parkinson’s disease The aim of the third trial is to see if NTCELL can pause or delay the natural progression of Parkinson’s disease With this funding...

The ASX saw a frenzy of M&A deals today and it sent the market higher. Companies completing deals included Ramelius Resources (ASX:RMS) buying Apollo Consolidated (ASX:AOP) and Class (ASX:CL1) being acquired by Hub24 (ASX:HUB) along wit...

It’s been a mixed week for the ASX but it has finished on a high. The ASX 200 closed 0.69% higher than yesterday, closing at 7,362 which marked a 3 week high but is still 3.5% above the all time high reached in mid-August. Travel stocks gai...

Summary Diagnostics company Rhythm Biosciences has confirmed that LRF enhancements have shown to improve ColoSTAT® results. Cannabis medicines developer Zelira Therapeutics has entered into a partnership with Alternative Solutions for...

It is with sorrow that AusBiotech acknowledges the passing of Living Cell Technologies (LCT) Founder, Emeritus Professor Sir Robert Elliott.

The sudden drop in spot gold prices and reintroduction of COVID-19 restrictions in New Zealand have hit the relevant ASX small caps this morning. After 100 days of being virus-free, four COVID-19 cases were detected in the country. New Zeal...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

A quick wrap of the key winners and losers on Monday, July 6. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 712 stocks rose, 576 declined and 819 were u...

A quick wrap of the key winners and losers on Friday, July 3. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 736 stocks rose, 584 declined and 789 were u...

A quick wrap of the key winners and losers on Monday, June 22. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow potentially made market-moving announcements during the day. Today 556 stocks rose, 793 declined a...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Investment bank Lazard believes shareholder activism is going to become more rife in future. Shareholder activism occurs when existing shareholders publically attempt to influence a company’s behaviour. To meet the criteria they have to be...

Generally, stocks are bifurcated into four categories based on their market capitalization: Large cap, Mid cap, Small cap and Penny Stocks. Large and mid-cap stocks offer lower risks and lower returns, but on the other hand, if we look at t...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...